Germline HLA-I genotypes predict pathologic response and survival outcomes in esophageal cancer patients undergoing neoadjuvant immunochemotherapy: a retrospective cohort study

Abstract Background Neoadjuvant immunochemotherapy (nICT) has reshaped the treatment paradigm for locally advanced esophageal cancer (EC), but patient responses remain highly heterogeneous. Reliable biomarkers to predict therapeutic benefit are urgently needed. Class I human leukocyte antigen (HLA-I...

Полное описание

Библиографические подробности

Главные авторы:	Willis Wasonga Omindo, Qi Wang, Siyou Deng, Ruijie Zhang, Wei Sun, Li Zhang, Ni Zhang
Формат:	Artigo
Язык:	Inglês
Опубликовано:	BMC 2026-05-01
Серии:	World Journal of Surgical Oncology
Предметы:	Esophageal cancer Neoadjuvant immunochemotherapy HLA class I genotype Pathologic complete response
Online-ссылка:	https://doi.org/10.1186/s12957-026-04374-8
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!